Literature DB >> 34017048

Epithelial-mesenchymal transition sensitizes breast cancer cells to cell death via the fungus-derived sesterterpenoid ophiobolin A.

Keighley N Reisenauer1, Yongfeng Tao2, Provas Das1, Shuxuan Song1, Haleigh Svatek1, Saawan D Patel1, Sheridan Mikhail1, Alec Ingros1, Peter Sheesley1, Marco Masi3, Angela Boari4, Antonio Evidente3, Alexander Kornienko5, Daniel Romo2, Joseph Taube6.   

Abstract

The epithelial-mesenchymal transition (EMT) imparts properties of cancer stem-like cells, including resistance to frequently used chemotherapies, necessitating the identification of molecules that induce cell death specifically in stem-like cells with EMT properties. Herein, we demonstrate that breast cancer cells enriched for EMT features are more sensitive to cytotoxicity induced by ophiobolin A (OpA), a sesterterpenoid natural product. Using a model of experimentally induced EMT in human mammary epithelial (HMLE) cells, we show that EMT is both necessary and sufficient for OpA sensitivity. Moreover prolonged, sub-cytotoxic exposure to OpA is sufficient to suppress EMT-imparted CSC features including sphere formation and resistance to doxorubicin. In vivo growth of CSC-rich mammary cell tumors, is suppressed by OpA treatment. These data identify a driver of EMT-driven cytotoxicity with significant potential for use either in combination with standard chemotherapy or for tumors enriched for EMT features.

Entities:  

Year:  2021        PMID: 34017048     DOI: 10.1038/s41598-021-89923-9

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  58 in total

Review 1.  Triple-negative breast cancer: an unmet medical need.

Authors:  Clifford A Hudis; Luca Gianni
Journal:  Oncologist       Date:  2011

Review 2.  Triple-negative breast cancer.

Authors:  William D Foulkes; Ian E Smith; Jorge S Reis-Filho
Journal:  N Engl J Med       Date:  2010-11-11       Impact factor: 91.245

3.  Response and prognosis of taxanes and anthracyclines neoadjuvant chemotherapy in patients with triple-negative breast cancer.

Authors:  Jiannan Wu; Shunrong Li; Weijuan Jia; Fengxi Su
Journal:  J Cancer Res Clin Oncol       Date:  2011-08-10       Impact factor: 4.553

Review 4.  Landscape of neoadjuvant therapy for breast cancer.

Authors:  Tufia C Haddad; Matthew P Goetz
Journal:  Ann Surg Oncol       Date:  2015-03-02       Impact factor: 5.344

5.  Pathological complete response in neoadjuvant treatment of breast cancer.

Authors:  Patricia Cortazar; Charles E Geyer
Journal:  Ann Surg Oncol       Date:  2015-03-02       Impact factor: 5.344

6.  Triple-negative breast cancer: clinical features and patterns of recurrence.

Authors:  Rebecca Dent; Maureen Trudeau; Kathleen I Pritchard; Wedad M Hanna; Harriet K Kahn; Carol A Sawka; Lavina A Lickley; Ellen Rawlinson; Ping Sun; Steven A Narod
Journal:  Clin Cancer Res       Date:  2007-08-01       Impact factor: 12.531

7.  The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.

Authors:  Lisa A Carey; E Claire Dees; Lynda Sawyer; Lisa Gatti; Dominic T Moore; Frances Collichio; David W Ollila; Carolyn I Sartor; Mark L Graham; Charles M Perou
Journal:  Clin Cancer Res       Date:  2007-04-15       Impact factor: 12.531

Review 8.  Triple-negative breast cancer.

Authors:  Reinaldo D Chacón; María V Costanzo
Journal:  Breast Cancer Res       Date:  2010-10-22       Impact factor: 6.466

9.  Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.

Authors:  W Fraser Symmans; Florentia Peintinger; Christos Hatzis; Radhika Rajan; Henry Kuerer; Vicente Valero; Lina Assad; Anna Poniecka; Bryan Hennessy; Marjorie Green; Aman U Buzdar; S Eva Singletary; Gabriel N Hortobagyi; Lajos Pusztai
Journal:  J Clin Oncol       Date:  2007-09-04       Impact factor: 44.544

10.  Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.

Authors:  Cornelia Liedtke; Chafika Mazouni; Kenneth R Hess; Fabrice André; Attila Tordai; Jaime A Mejia; W Fraser Symmans; Ana M Gonzalez-Angulo; Bryan Hennessy; Marjorie Green; Massimo Cristofanilli; Gabriel N Hortobagyi; Lajos Pusztai
Journal:  J Clin Oncol       Date:  2008-02-04       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.